SwePub
Sök i LIBRIS databas

  Extended search

L773:0002 8703 OR L773:1097 6744
 

Search: L773:0002 8703 OR L773:1097 6744 > (2015-2019) > Outcomes of apixaba...

  • Alexander, Karen P (author)

Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity : Insights from the ARISTOTLE trial

  • Article/chapterEnglish2019

Publisher, publication year, extent ...

  • Elsevier BV,2019
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-374972
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374972URI
  • https://doi.org/10.1016/j.ahj.2018.09.017DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Patients with atrial fibrillation (AF) often have multi-morbidity, defined as ≥3 comorbid conditions. Multi-morbidity is associated with polypharmacy, adverse events, and frailty potentially altering response to anticoagulation. We sought to describe the prevalence of multi-morbidity among older patients with AF and determine the association between multi-morbidity, clinical outcomes, and the efficacy and safety of apixaban compared with warfarin.METHODS: In this post-hoc subgroup analysis of the ARISTOTLE trial, we studied enrolled patients age ≥ 55 years (n = 16,800). Patients were categorized by the number of comorbid conditions at baseline: no multi-morbidity (0-2 comorbid conditions), moderate multi-morbidity (3-5 comorbid conditions), and high multi-morbidity (≥6 comorbid conditions). Association between multi-morbidity and clinical outcomes were analyzed by treatment with a median follow-up of 1.8 (1.3-2.3) years.RESULTS: Multi-morbidity was present in 64% (n = 10,713) of patients; 51% (n = 8491) had moderate multi-morbidity, 13% (n = 2222) had high multi-morbidity, and 36% (n = 6087) had no multi-morbidity. Compared with the no multi-morbidity group, the high multi-morbidity group was older (74 vs 69 years), took twice as many medications (10 vs 5), and had higher CHA2DS2-VASc scores (4.9 vs 2.7) (all P < .001). Adjusted rates per 100 patient-years for stroke/systemic embolism, death, and major bleeding increased with multi-morbidity (Reference no multi-morbidity; moderate multi-morbidity 1.42 [1.24-1.64] and high multi-morbidity 1.92 [1.59-2.31]), with no interaction in relation to efficacy or safety of apixaban.CONCLUSIONS: Multi-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Brouwer, Marc A (author)
  • Mulder, Hillary (author)
  • Vinereanu, Dragos (author)
  • Lopes, Renato D (author)
  • Proietti, Marco (author)
  • Al-Khatib, Sana M (author)
  • Hijazi, ZiadUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)ziahi940 (author)
  • Halvorsen, Sigrun (author)
  • Hylek, Elaine M (author)
  • Verheugt, Freek W A (author)
  • Alexander, John H (author)
  • Wallentin, Lars,1943-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi,UCR(Swepub:uu)larswall (author)
  • Granger, Christopher B (author)
  • Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Related titles

  • In:American Heart Journal: Elsevier BV208, s. 123-1310002-87031097-6744

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view